🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07606794
Recruiting Not applicable

Supra-Iliac Anterior Quadratus Lumborum Block and Pericapsular Nerve Group (PENG) Block for Analgesia After Total Hip Arthroplasty

NCT07606794 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-05-23
Last updated
2026-06-23

Condition(s) studied

Supra-Iliac Anterior Quadratus Lumborum BlockPericapsular Nerve Group BlockAnalgesiaTotal Hip Arthroplasty

Investigational drug(s) / intervention(s)

Supra-iliac anterior quadratus lumborum blockPericapsular nerve group block

Supra-iliac anterior quadratus lumborum block: Patients will receive a supra-iliac anterior quadratus lumborum block (SA-QLB) using 20mL of bupivacaine 0.25%.

Pericapsular nerve group block: Patients will receive an ultrasound-guided pericapsular nerve group (PENG) block using 20mL of bupivacaine 0.25%.

Study summary

This study aims to compare the analgesic efficacy of supra-iliac anterior quadratus lumborum block (SA-QLB) and pericapsular nerve group (PENG) block in patients undergoing total hip arthroplasty (THA).

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age from 18 to 75 years. * Both sexes. * American Society of Anesthesiologists (ASA) classification I-III. * Scheduled for primary elective unilateral total hip arthroplasty (THA) under spinal anesthesia. Exclusion Criteria: * Known allergies to the drugs used. * Infection at the injection site. * Bleeding disorders. * Recognized neuromuscular disorders. * Opioid addiction or dependence. * Contraindications to regional anesthesia or peripheral nerve blockade. * Body mass index (BMI) \> 40 kg/m². * Associated decompensated cardiac, hepatic, respiratory, or renal diseases.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tanta University Tanta El-Gharbia Recruiting

More Tanta University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07606794 on ClinicalTrials.gov ↗ ← All trials in Egypt